Vincerx Pharma, Inc. Common Stock - Asset Resilience Ratio
Vincerx Pharma, Inc. Common Stock (VINC) has an Asset Resilience Ratio of 47.80% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vincerx Pharma, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how Vincerx Pharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Vincerx Pharma, Inc. Common Stock.
Liquid Assets Composition Over Time
This chart breaks down Vincerx Pharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Vincerx Pharma, Inc. Common Stock for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.14 Million | 47.8% |
| Total Liquid Assets | $7.14 Million | 47.80% |
Asset Resilience Insights
- Very High Liquidity: Vincerx Pharma, Inc. Common Stock maintains exceptional liquid asset reserves at 47.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vincerx Pharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Vincerx Pharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Vincerx Pharma, Inc. Common Stock (2021–2023)
The table below shows the annual Asset Resilience Ratio data for Vincerx Pharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $18.22 Million | -- |
| 2022-12-31 | 68.81% | $40.80 Million | $59.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $117.68 Million | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more